50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

US FDA approves Mesoblast's cell therapy for graft-versus-host disease

Published 12/18/2024, 04:57 PM
Updated 12/19/2024, 04:51 AM
© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
MESO
-

(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Mesoblast (NASDAQ:MESO)'s cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called graft-versus-host disease (GVHD).

The therapy, branded as Ryoncil, is the first mesenchymal stromal cell therapy approved to treat pediatric patients aged two months and older whose GVHD symptoms have not responded to standard steroid therapy.

The company did not immediately respond to Reuters request for comment on pricing and availability.

GVHD is a complication that might occur after a cell transplant, where the donated stem cells attack the recipient’s cells, viewing them as an unfamiliar threat.

Mesenchymal stromal cells are spindle-shaped cells that can have various roles in the body and can differentiate into multiple other types of cells. The cells are isolated from the bone marrow of healthy adult human donors.

© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo

The FDA advises the treating physician should monitor the Ryoncil infusion, and discontinue it if there is any evidence of a reaction such as shortness of breath, low blood pressure, fever, or rapid breathing, among others.

Last year, the U.S. health regulator declined to approve the therapy as it required more data to support marketing approval.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.